3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
3
Lymphoid
3
Other
2
Head & Neck
2
Gastrointestinal
2
CNS
2
Tumor-Agnostic
1
NET
1
Gynecologic
1
Endocrine
1
Conditions
Stomatitis
2
Mucositis
2
Mouth Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
1
Interventions
naloxegol
7
alvimopan
6
Radiotherapy
5
angiotensin I (1-7)
4
Cisplatin
4
tegaserod
3
Injections
3
RRx-001
2
Fibroblast Growth Factor 7
2
tempol
1
prucalopride
1
oxycodone naloxone combination
1
naldemedine
1
methylnaltrexone
1
linaclotide
1
licogliflozin
1
hydrated silica gel-based toothpaste
1
golotimod
1
brilacidin
1
apraglutide
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Water
1
Therapeutics
1
Testosterone Propionate
1
Robotic Surgical Procedures
1
Radiotherapy, Intensity-Modulated
1
Phenylephrine
1
Oxycodone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
RRx-001
×
Other
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts